These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35335001)

  • 1. Gam-COVID-Vac (Sputnik V) and Pfizer-BioNTech Vaccines Adverse Events following Immunization in Patients Affected by Parkinson's Disease and Multiple Sclerosis: A Longitudinal Study.
    Soldà G; Barvas E; Lenzi J; Di Valerio Z; La Fauci G; Guttmann S; Riccardi R; Fantini MP; Salussolia A; Montalti M; Gori D
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35335001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance.
    Di Valerio Z; La Fauci G; Soldà G; Montalti M; Lenzi J; Forcellini M; Barvas E; Guttmann S; Poluzzi E; Raschi E; Riccardi R; Fantini MP; Salussolia A; Gori D
    EClinicalMedicine; 2022 Jul; 49():101468. PubMed ID: 35614901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance.
    Montalti M; Soldà G; Di Valerio Z; Salussolia A; Lenzi J; Forcellini M; Barvas E; Guttmann S; Messina R; Poluzzi E; Raschi E; Riccardi R; Fantini MP; La Fauci G; Gori D;
    EClinicalMedicine; 2021 Aug; 38():101027. PubMed ID: 34505029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study.
    Zeitoun A; Hallit S; Chehade S; Ibrahim A; Helali M; Allam C; Karam R
    J Pharm Policy Pract; 2023 Feb; 16(1):24. PubMed ID: 36810279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacist-directed Sputnik V (GAM-COVID-VAC) surveillance program: a prospective observational study in Southern India.
    Karattuthodi MS; Chandrasekher D; Panakkal LM; C S; Salman M; Megha ; E MS; Fasil M; A M M; Reji M
    J Basic Clin Physiol Pharmacol; 2023 Jul; 34(4):509-517. PubMed ID: 35172420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Safety Profile of COVID-19 Vaccines in Patients Diagnosed with Multiple Sclerosis: A Retrospective Observational Study.
    Maniscalco GT; Scavone C; Mascolo A; Manzo V; Prestipino E; Guglielmi G; Aiezza ML; Cozzolino S; Bracco A; Moreggia O; Di Giulio Cesare D; Ziello AR; Falco A; Massa M; Majolo M; Raiola E; Soprano R; Russo G; Longo G; Andreone V; Capuano A
    J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
    Duijster JW; Lieber T; Pacelli S; Van Balveren L; Ruijs LS; Raethke M; Kant A; Van Hunsel F
    Front Immunol; 2023; 14():1078736. PubMed ID: 36793715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.
    Ogar CK; Quick J; Gilbert HN; Vreman RA; Mantel-Teeuwisse AK; Mugunga JC
    Drug Saf; 2023 Apr; 46(4):357-370. PubMed ID: 36811813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally.
    ShamaeiZadeh PA; Jaimes CV; Knoll MD; Espié E; Chandler RE
    Vaccine X; 2024 Jun; 18():100485. PubMed ID: 38655548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand.
    Sirisuk W; Limvorapitak W; Lolekha P; Methaset K; Kulkantrakorn K
    Clin Neurol Neurosurg; 2023 Aug; 231():107804. PubMed ID: 37295197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System.
    Nikitina V; Santi Laurini G; Montanaro N; Motola D
    Acta Paediatr; 2023 Nov; 112(11):2426-2433. PubMed ID: 37608686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
    Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Population-Based Structures to Actively Monitor AEFIs during a Mass Immunization Campaign-A Case of Measles-Rubella and Polio Vaccines.
    Kajungu D; Nambasa V; Muhoozi M; Tusabe J; Kampmann B; Todd J
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.